Abstract
We report that a postmenopausal woman with osteoporosis developed bilateral incomplete atypical femoral fractures (AFFs) after seven years of bisphosphonate therapy. Cessation of the bisphosphonate and treatment with teriparatide was associated with near complete radiological resolution of the AFFs. After 12 months without treatment, denosumab was commenced to prevent structural deterioration. Six months later she developed recurrent bilateral AFFs. This case highlights the management dilemma in patients with ongoing bone loss but prone to stress fractures associated with antiresorptive therapy. Stopping the antiresorptive is recommended but structural decay will recur predisposing to fragility fractures. If the antiresorptive is continued, bone material composition will be further compromised predisposing to atypical fractures. Teriparatide may assist healing of stress fractures and improvement in bone matrix composition. Later antiresosrptive therapy to preserve bone microstructure may compromise material composition.
Similar content being viewed by others
References
Zebaze R, Ghasem-Zadeh A, Mbala A, Seeman E (2013) A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images. Bone 54(1):8–20
Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354(21):2250–2261
Diab DL, Watts NB (2014) Denosumab in osteoporosis. Expert Opin Drug Saf 13(2):247–253
Ettinger B, Burr DB, Ritchie RO (2013) Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 55(2):495–500
Karim L, Vashishth D (2012) Heterogeneous glycation of cancellous bone and its association with bone quality and fragility. PLoS One 7(4):e35047
Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69(5):281–286
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23
Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52(1):360–365
Murphy CM, Schindeler A, Cantrill LC, Mikulec K, Peacock L, Little DG (2014) PTH treatment increases bisphosphonate turnover in fracture repair in rats. J Bone Miner Res 30(6):1022–2029
Miller PD, McCarthy EF (2015) Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Semin Arthritis Rheum 44(5):477–482
Bardin MS, Iuliano-Burns S, Zajac J, Seeman E, Chiang C (2013) Patients with atypical femoral fractures have higher body mass index and femoral neck bone mineral density compared to patients with typical femoral fractures. Paper presented at: Endocrine Society of Australia - Annual Scientific Meeting; Sydney, Australia.
Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47(2):169–180
Bala Y, Farlay D, Delmas PD, Meunier PJ, Boivin G (2010) Time sequence of secondary mineralization and microhardness in cortical and cancellous bone from ewes. Bone 46(4):1204–1212
Thompson RN, Armstrong CL, Heyburn G (2014) Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. Bone 61:44–47
Gallant MA, Brown DM, Hammond M, Wallace JM, Du J, Deymier-Black AC, Almer JD, Stock SR, Allen MR, Burr DB (2014) Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties. Bone 61:191–200
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Roger M Zebaze and Ego Seeman are directors of StraxCorp and inventors of the algorithm for quantifying tissue mineralization density. No financial compensation was derived from this work. Sabashini K Ramchand and Cherie Y Chiang declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Ramchand, S.K., Chiang, C.Y., Zebaze, R.M. et al. Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report. Osteoporos Int 27, 821–825 (2016). https://doi.org/10.1007/s00198-015-3354-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-015-3354-0